RecruitingNCT03981003

Serum Neurofilament-light Chain and GFAP Levels in Patients From the OFSEP Cohort at Different Landmarks of Multiple Sclerosis

Serum Neurofilament-light Chain and Glial Fibrillary Acidic Proten (GFAP) Levels in Patients From the OFSEP Cohort at Different Landmarks of Multiple Sclerosis


Sponsor

Centre Hospitalier Universitaire de Nīmes

Enrollment

1,150 participants

Start Date

May 22, 2019

Study Type

OBSERVATIONAL

Conditions

Summary

The investigators hypothesize that serum neurofilament-light chain (NfL) levels can provide information about the level of activity and progression of Multiple Sclerosis at different stages and landmarks of the disease. In addition, Glial Fibrillary Acidic Protein (GFAP) has also been identified as another serum biomarker of disability in MS.


Eligibility

Min Age: 15 Years

Inclusion Criteria10

  • The patient has been correctly informed.
  • The patient must have given their informed and signed consent.
  • The patient must be insured or beneficiary of a health insurance plan.
  • The patient is at least (≥)15 years old.
  • The patient has MS according to diagnosis criteria (Thompson et al. 2017) and:
  • Participates to the OFSEP-HD cohort (ancillary study);
  • Has a Expanded Disability Status Scale score comprised between 0 - 7.0;
  • With or without Disease Modifying Drug;
  • For Work Package 3: patients enrolled in any OFSEP-HD centre that meet landmark criteria for an active MS (relapse, or Expanded Disability Status Scale progression, or active MRI) during follow-up;
  • For Work Package 4: patients with a stable disease enrolled in OFSEP-HD study in Nîmes or Nantes University Hospitals.

Exclusion Criteria11

  • Within the past three months, the patient has participated in another interventional study that may interfere with the results or conclusions of this study.
  • The patient is in an exclusion period determined by a previous study.
  • The patient is under judicial protection.
  • The patient refuses to sign the consent.
  • It is impossible to correctly inform the patient (inability to understand the study, language problem).
  • The patient is pregnant or breast-feeding.
  • The patient is under 15 years old.
  • Inability to answer questionnaires.
  • Clinically isolated syndrome (CIS) that does not meet the criteria of MS.
  • Radiologically isolated syndrome (RIS).
  • Patient with Neuromyelitis optica spectrum disorder.

Interventions

DIAGNOSTIC_TESTBlood sample

2 x 4 ml tubes blood to screen for serum Neurofilament Light Chain and GFAP levels


Locations(28)

CHU d'Amiens

Amiens, France

CHU de Besancon

Besançon, France

CHU de Bordeaux

Bordeaux, France

CHU de Caen

Caen, France

CHU de Clermont Ferrand

Clermont-Ferrand, France

Hopital Henri Mondor

Créteil, France

CHU de Dijon

Dijon, France

CHU de Grenoble

Grenoble, France

CHU de Lille

Lille, France

CHU de Limoges

Limoges, France

CHU de Lyon

Lyon, France

Hopital Timone

Marseille, France

CHU de Montpellier

Montpellier, France

CHU de Nancy

Nancy, France

CHU de Nice

Nice, France

CHU de Nimes

Nîmes, France

Fondation Rothschild

Paris, France

Hopital Pitie Salpetriere

Paris, France

Hopital Saint Antoine

Paris, France

CH de Poissy

Poissy, France

CHU de Potiers

Potiers, France

CHU de Rennes

Rennes, France

CHU de Rouen

Rouen, France

CHU de Saint Etienne

Saint-Etienne, France

CHU de Strasbourg

Strasbourg, France

CHU de Toulouse

Toulouse, France

CHU de Tours

Tours, France

CHU de Martinique

Fort-de-France, Martinique

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03981003


Related Trials